biologic

Sucraid

sacrosidase

Loss of exclusivityMay 2034projected — 12-year biologic exclusivity estimate
CompanyQOL MedicalView the full company profile on CliffBio

Drug detail

Brand nameSucraid
Active ingredientsacrosidase
Strength17,000IU/2ML (8,500IU/ML)
Dosage formSolution For Oral
RouteOral
ModalityBiologic
FDA approvalMay 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sucraid patent cliff — loss of exclusivity May 2034 | CliffBio